FDA's Budget Path To Biosimilars: 21 Applications By 2015?
You may also be interested in...
A Federal Register notice outlines the new user fee amounts and suggests that President Obama’s budget projections anticipated as many as 10 marketing applications, but the mix of INDs and full applications is unknown.
Other aspects of FDA's approach to drugs and biologics remain the same as they were in last September's draft version of the agency's five-year plan.
Regulatory science improvements, a casualty of last year’s budget process, would be saved in President Obama’s fiscal year 2012 budget, although in part because some of the infrastructure already is under construction.